China National Medical Products Administration

July 23, 2020July 23, 2020

PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer

News

China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. ... Read more

March 20, 2020March 20, 2020

China Reviewing Zejula as First-line Therapy for Ovarian Cancer

News

The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding to ... Read more